# Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

> **NCT05961761** · PHASE2 · RECRUITING · sponsor: **Niels Junker** · enrollment: 80 (estimated)

## Conditions studied

- Soft Tissue Sarcoma Adult
- Angiosarcoma
- Undifferentiated Pleomorphic Sarcoma

## Interventions

- **DRUG:** Propranolol
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05961761
- **Lead sponsor:** Niels Junker
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-17
- **Primary completion:** 2028-01
- **Final completion:** 2028-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05961761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05961761, "Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05961761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*